An Empirical Regression Approach to Estimating Blood Pressure Components [PDF]
, 2018 Nofiu Idowu Badmus
openalex +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology, EarlyView.Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Clinical Validation of Global Coagulation Tests to Guide Blood Component Transfusions in Cirrhosis and ACLF. [PDF]
J Clin Transl Hepatol, 2021 Premkumar M +10 more
europepmc +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve. [PDF]
Transfusion, 2021 DeSimone RA +9 more
europepmc +1 more source
Comparative Forensic Characterization of Blood Components by Increased Alcoholic Concentrations [PDF]
, 2022 Charu Charu +2 more
openalex +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Blood Component Transfusion in a Tertiary Care Hospital. [PDF]
Indian J Pediatr, 2020 Sharif M +4 more
europepmc +1 more source
A pilot study of stored low titer group O whole blood + component therapy versus component therapy only for civilian trauma patients. [PDF]
J Trauma Acute Care Surg, 2021 Siletz AE +12 more
europepmc +1 more source
Molecular Oncology, EarlyView.We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck +12 more
wiley +1 more source